

Sawai Group corporate philosophy

Always putting healthier lives first

The Sawai Group corporate philosophy of “always putting healthier lives first” embodies our desire to contribute to the health of as many people as possible as a healthcare corporate group which develops sustainably alongside society, with the generic drugs business as our core business. We will mobilize the strengths of all Group employees to pursue the challenge of meeting the expectations of all stakeholders.

Sawai Group Mind



The Sawai Group will serve every stakeholder wholeheartedly.
 The Sawai Group will continue the challenge to improve access to healthcare for more people.
 The Sawai Group aspires to play a pivotal role in healthcare through its contribution to society.



Contents

7 Management message	15 Our value creation story	27 Value creation strategy	43 Governance
7 Message from CEO	15 Our value creation model	27 Medium-Term Business Plan	43 Roundtable discussion
13 Inappropriate testing investigation results and recurrence prevention measures	17 The Sawai Group strengths	29 Japanese generics business	47 Board of Directors
	21 Sustainability at the Sawai Group	33 New businesses	49 Corporate governance
	25 Financial and non-financial highlights	35 Human asset strategy	
		39 Financial strategy	53 Eleven-year financial and non-financial summary
		41 Environment	

Editorial policy

This report references the International Financial Reporting Standards Foundation's International Integrated Report Framework and includes information that could impact our medium- to long-term corporate value creation and that is connected with information about the Company's strategies, performance, and future projections, as well as non-financial information concerning the environment, society, and governance. The contents herein have been assigned priority internally based on their nature and quantity, risks, opportunities, and dialogues with stakeholders, and have been deemed to be of particular importance.
 This report has been prepared by the Group Sustainability Committee, which is supervised by the President, and with the support of the committee's administrative office.

Reporting period:
 April 1, 2023 to March 31, 2024
 (some information herein falls outside of this period)

Abbreviations used:
 In this report, “generic drugs” are abbreviated as either “GE drugs” or “GE.”

A caution concerning forward-looking statements:
 This report contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication. Accordingly, please be aware that the impact of certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report.

Reporting scope:
 Sawai Group Holdings and its consolidated subsidiaries

Group history


Not only “always putting patients first”
but also striving to succeed in
“always putting healthier lives first”
for all people



1929
Sawai Pharmacy, the predecessor of Sawai Pharmaceutical Co., Ltd., was founded in Asahi-ku, Osaka City.

1948
Sawai Pharmaceutical Co., Ltd. was incorporated in Asahi-ku, Osaka City.

1965
Shifted from making OTC drugs to ethical pharmaceuticals.



1929–
Sawai Pharmacy founded in Asahi-ku Osaka as local pharmacy
Sawai Pharmaceutical's history starts almost 90 years ago. Hanpei Sawai and Noyo Sawai (a pharmacist) established Sawai Pharmacy, Sawai Pharmaceutical's predecessor. At that time, there were few pharmacies, and Sawai Pharmacy supported the health of residents by providing drugs as a local pharmacy.

1965–
Transformed into manufacturer of prescription medications and then into a leading GE company
In response to changes in the drug market due to the introduction of a universal medical care insurance system, Sawai transformed itself from a manufacturer of over-the-counter medications into a manufacturer of prescription medications. By supplying one product after another that meet the needs of healthcare professionals, we have built a foundation to grow into a leading company in the generic drug industry.

2003–
Contributed to spreading and expanding GE as a company listed on the First Section of the Tokyo Stock Exchange
In line with the basic policies of expanding market share, further strengthening the management structure, and building a solid Sawai brand, Sawai continued to grow, boosted by the tail wind of government policies to promote the use of generic drugs. We also strengthened our production and development capabilities, which included construction of the Kanto and Sanda Nishi factories and a new development center.

2021–
Transformed into GE manufacturer that continues to be selected with an eye toward industry reorganization
Sawai transitioned to a holding company structure in 2021 in order to strengthen its existing businesses and foster new businesses that meet the needs of the time. In fiscal 2022, revenue exceeded ¥200.0 billion (including discontinued operations), as the Company worked to provide a stable supply of inexpensive, high-quality generic drug as social infrastructure.



Group vision

Pursuing all people's health from all perspectives as a general healthcare company

Sawai Group Vision 2030

The World We Want to Build

A world where more people can receive healthcare services and live a full life with peace of mind among society

Our Ideal State

A company with a strong presence that continues to contribute to people's health by providing a multifaceted mix of products and services that meet individual needs based on scientific evidence

Medium-Term Business Plan "Beyond 2027" → P. 27

Giving top priority to establishing a trusted corporate foundation, and setting key themes for business strategy and business foundation

Key themes for business strategy

- 1 Achieving steady growth in the generics market
- 2 Establishing sustainability of the generics business
- 3 Continuing investment in growth areas

Key business foundation themes

- 1 Creating talent that underpins sustainable growth
- 2 Working on sustainability initiatives
- 3 Improving capital efficiency

Value created by The Sawai Group

Leading the way in the promotion of generic drugs as an industry pioneer

Sales volume

Approx.
15.7
billion tablets
Sawai Pharmaceutical

Share of Japan's prescription drug market (volume)

Approx.
8.4%
Sawai estimate

Amount of reduction in healthcare costs

Approx.
¥293.9
billion
Japan business

Number of products on sale

Approx.
770

Production system

8
facilities
throughout Japan

